Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
![]() OGN In 1 weeks Estimated | Quarterly | $0.02 Per Share |
![]() OGN 2 months ago Paid | Quarterly | $0.02 Per Share |
![]() OGN 5 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 8 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 11 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 10 May 2024 Paid | Quarterly | $0.28 Per Share |
29 Oct 2025 (In 3 months) Date | | 0.94 Cons. EPS | - EPS |
12 Aug 2025 (In 1 week) Date | | 0.94 Cons. EPS | - EPS |
5 Aug 2025 (In 6 days) Date | | 0.94 Cons. EPS | - EPS |
30 Apr 2025 Date | | 1.01 Cons. EPS | - EPS |
13 Feb 2025 Date | | 0.87 Cons. EPS | 0.9 EPS |
![]() OGN In 1 weeks Estimated | Quarterly | $0.02 Per Share |
![]() OGN 2 months ago Paid | Quarterly | $0.02 Per Share |
![]() OGN 5 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 8 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 11 months ago Paid | Quarterly | $0.28 Per Share |
![]() OGN 10 May 2024 Paid | Quarterly | $0.28 Per Share |
29 Oct 2025 (In 3 months) Date | | 0.94 Cons. EPS | - EPS |
12 Aug 2025 (In 1 week) Date | | 0.94 Cons. EPS | - EPS |
5 Aug 2025 (In 6 days) Date | | 0.94 Cons. EPS | - EPS |
30 Apr 2025 Date | | 1.01 Cons. EPS | - EPS |
13 Feb 2025 Date | | 0.87 Cons. EPS | 0.9 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Kevin Ali CEO | NYSE Exchange | 68622V106 Cusip |
US Country | 10,000 Employees | 24 Feb 2025 Last Dividend | - Last Split | 2 Jun 2021 IPO Date |
Organon & Co. is a healthcare company focused on innovating and providing a range of health solutions specifically tailored towards women's health needs both in the United States and globally. The company's diverse product offering encompasses a variety of prescription therapies and medical devices. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. has quickly positioned itself as a key player in women's health, extending its reach through a broad spectrum of contraception and fertility treatments, biosimilars, and other healthcare solutions. Their mission extends to addressing critical areas such as cardiovascular health, respiratory conditions, dermatology, bone health, and non-opioid pain management, catering to a wide demographic. Through its commitment to health innovation, Organon & Co. markets its products to a vast network of stakeholders including drug wholesalers, retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.